.Nature Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after an average consequence of 11 months, patients with metastatic stomach cysts that got biomarker-matched treatments based upon flowing cyst DNA profiling showed a greater scientific perk than those obtaining unequaled therapy.